anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGICAL RELEVANCE: Gout, a painful joint disease with a prevalence ranging from 0.86% to 2.2% in China over the past decade. Traditional medicine has long utilized the medicinal and edible Piper longum L. (PL) fruit spikes for treating gout and other joint conditions like rheumatoid arthritis. However, the exact mechanisms behind its effectiveness remain unclear.
AIM OF THE STUDY: This study aimed to investigate the potential of alcoholic extracts from PL fruit spikes as a safe and effective treatment for gout. We used a combined network pharmacology and experimental validation approach to evaluate the mechanisms behind the anti-gout properties of PL.
MATERIALS AND METHODS: UPLC-Q/TOF-MS analysis determined the major components of PL. Subsequently, network pharmacology analysis predicted potential molecular targets and related signaling pathways for the anti-gout activity of PL. Molecular docking simulations further explored the interactions between PL compounds and proteins and characterized the properties of potential bioactive secondary metabolites. Mouse models of air pouch inflammation and hyperuricemia were further established, and the anti-gout mechanism of PL was confirmed by examining the expression of proteins related to the MAPK and PI3K-AKT pathways in the tissue.
RESULTS: Our analysis revealed 220 bioactive secondary metabolites within PL extracts. Network pharmacology and molecular docking results indicated that these metabolites primarily combat gout by modulating the PI3K-AKT and MAPK signaling pathways. In vivo experiments have also proven that PL at a dose of 100 mg/kg can optimally reduce acute inflammation of gout and kidney damage caused by high uric acid. The anti-gout mechanism involves the PI3K-AKT/MAPK signaling pathway and its downstream NF-κB pathway.
CONCLUSION: This study provides compelling evidence for PL's therapeutic potential in gout management by modulating key inflammatory pathways. The findings offer a strong foundation for future clinical exploration of PL as a gout treatment option.
<P>PROBLEM TO BE SOLVED: To provide a consumable item management server, method and program for detecting the weight increase/decrease of each medicine in real time by a single scale and a single RFID reader and furthermore detecting the consumption of the medicine.  <P>SOLUTION: A plurality of medicine containers 4 have RFID tags attached thereto. Tag IDs for identifying the medicine containers are added to the RFID tags. A medicine table 2 with an RFID reader reads the respective tag IDs at every fixed time from the medicine containers 4 with the RFID tags attached thereto, and transmits them to a management server 3. The scale 1 reads the total weight of the plurality of medicine containers 4 at every fixed time and transmits it to the management server 3. The management server 3 receives the tag IDs of the medicine containers 4 from the medicine table 2 with the RFID reader, and the total weight of the medicine containers 4 from the scale 1, and manages the medicines.  <P>COPYRIGHT: (C)2007,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To read code images on more appropriate reading conditions than reading all the code images on the same reading conditions.  <P>SOLUTION: A digital pen 600 is switched to a writing mode or reference information acquisition mode when a switch 68 is depressed. In the writing mode, a pen tip 69 provides writing on printed matter 500, and an infrared LED unit 63 and an infrared CMOS 64 capture code pattern images on the printed matter 500 at sixty frames per second. In the reference information acquisition mode, code pattern images in particular areas on the printed matter 500 are captured at ten frames per second. The reference information acquisition mode adopts a larger light quantity of the infrared LED unit 63, a wider radiation area on the printed matter 500 and a longer driving pulse width than the writing mode.  <P>COPYRIGHT: (C)2009,JPO&INPIT
An inhalable composition comprising one or more cannabinoids, or a pharmaceutically acceptable derivative or salt thereof, a propellant comprising HFA-152a (1,1-difluoroethane, R-152a), and a glycol and/or glycol ether. The composition may comprise less than 1 %w/w ethanol, 0.5 %w/w ethanol, or be free of ethanol. The cannabinoids may be selected from tetrahydrocannabinol (THC), dronabinol, cannabidiol (CBD), cannabinol (CBD), tetrahydrocannabivarin (THCV), cannabigerol (CBG), cannabidivarin (CBDV), cannabichromene (CBC), and may be present from 0.01-15 %w/w. The glycol may be selected from propylene glycol, polypropylene glycol, polyethylene glycol, or combinations. The composition may also comprise a TAS2R bitter taste receptor agonist, which may be saccharin, and may also comprise a flavour component, which may be selected from peppermint oil, aniseed, chocolate, coco, menthol, and vanillin. The inhalable composition may be used as a medicament in the treatment of a subject where the aerosol has a fine particle fraction of 60% or more, and the subject may be suffering from neuropathic pain, cannabis addiction, nausea, motion sickness, arthritis, and neurodegenerative diseases. Also provided is an inhalable composition further comprising a monohydric alcohol. Also provided is a cannabinoid inhaler containing the inhalable composition.
Hemodialysis is the lifeline for nearly three million end stage renal disease patients worldwide. Native arteriovenous fistula (AVF) is the preferred vascular access, but 40% fail within 1 year. We recently demonstrated that AVFs harbour transitional flows and the goal of the present study was to investigate whether the associated high-frequency pressure fluctuations could promote vibrations within the vascular wall. We acquired MRI images and flow rates immediately after surgery in one patient and generated a 3D patient-specific model. High-fidelity fluid structure interaction simulations revealed the presence of wall vibrations in distinct frequency bands up to 200 Hz and amplitude of 200 μm. A sensitivity analysis to assess the impact of flow rates, and vascular wall stiffness and thickness, changes that typically occur during AVF maturation, confirmed the robustness of the results. Interestingly, the vibrations were always predominant at the anastomosis floor and on the inner venous side, which correlates with typical stenotic regions. As studies seeking to correlate aberrant stresses and vascular remodelling have been largely inconclusive, the focal colocalization between vibrations and stenosis may suggest an unknown mechanobiological process between high-frequency mechanical stresses within the vascular wall and adverse vascular remodelling.
PCT No. PCT/JP94/01254 Sec. 371 Date Mar. 29, 1995 Sec. 102(e) Date Mar. 29, 1995 PCT Filed Jul. 29, 1994 PCT Pub. No. WO95/03879 PCT Pub. Date Feb. 9, 1995A phase-separated membrane in which the control of permeation rate and the control of permeation amount of a minute amount of drugs or other chemical substances are easily performed is provided. The phase-separated membrane has a constitution that a crosslinked gelatin phase 1 and an uncrosslinked segmented polyurethane phase 2 are present as a mixture. The segmented polyurethane phase is in a solid state at ordinary temperatures and is molten into a liquid state at 30 DEG  to 40 DEG  C. which is near the temperature of human skin.
A novel cell growth regulatory factor, named Amphiregulin, is described. This extremely hydrophilic glycoprotein, having a median molecular weight of 22,500 daltons, demonstrates unusual biological activity. Amphiregulin is a bifunctional cell growth regulatory factor which exhibits potent inhibitory activity on DNA synthesis in neoplastic cells, yet promotes the growth of certain normal cells. The invention is based, in part, on the discovery that MCF-7 cells, when treated with the tumor promoting agent, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), express and secrete two distinct yet functionally equivalent forms of Amphiregulin. These two forms are structurally identical and perfectly homologous except that the truncated form lacks an amino-terminal hexapeptide found in the larger form. The Amphiregulin gene has been cloned and used to construct plasmids which direct the expression of bioactive Amphiregulin in transformed Escherichia coli cells. A wide variety of uses for Amphiregulin are encompassed by the present invention, including the treatment of wounds and cancers.
The invention discloses a Chinese medical compound preparation for treating skin injury. The Chinese medical compound preparation includes active component extracts and auxiliary materials. The active component extracts are prepared from 1-20 parts of Resina Draconis, or 3-25 parts of Olibanum, 3-25 parts of Myrrha, or 1-20 parts of Resina Draconis, 3-15 parts of Olibanum 3 to 25 parts, 3-25 parts of Myrrha; 3-30 parts of Radix Angelicae Sinensis, 3-35 parts of Rhizoma Chuanxiong, 3-20 parts of Ramulus Cinnamomi and 1-15 parts of Herba Asari. The Chinese medical compound preparation has the advantages of reasonable formulation, remarkable effect, and little toxic effect. The fat-soluble components or volatile oils of Resina Draconis, Olibanum, Myrrha, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Ramulus Cinnamomi and Herba Asari not only are the effective component, but serve as the percutaneous absorption promoter. The effective components of the preparation are extracted effectively by the modern technology, and can be prepared to the forms suiting the skin diseases. The Chinese medical compound preparation can be used for skin injury caused by chemical substances and skin burn injury.
EBV+ lymphomas constitute a significant cause of morbidity and mortality in recipients of allogeneic hematopoietic cell (HCT) and solid organ transplants (SOT). Phase I and II trials have shown that in HCT recipients, adoptive transfer of EBV-specific T-cells from the HCT donor can safely induce durable remissions of EBV+ lymphomas including 70->90% of patients who have failed to respond to treatment with Rituximab. More recently, EBV-specific T-cells generated from allogeneic 3rd party donors have also been shown to induce durable remission of EBV+ lymphomas in Rituximab refractory HCT and SOT recipients. In this review, we compare results of phase I and II trials of 3rd party and donor derived EBV-specific T-cells. We focus on the attributes and limitations of each product in terms of access, safety, responses achieved and durability. The limited data available regarding donor and host factors contributing to T cell persistence is also described. We examine factors contributing to treatment failures and approaches to prevent or salvage relapse. Lastly, we summarize strategies to further improve results for virus-specific immunotherapies for post-transplant EBV lymphomas.
Stroke has been one of the most important causes of disability and death worldwide today. Ischemic stroke accounts for more than 50% of these strokes. The results of epidemiological surveys show that in 2018, more than 3 million new strokes occurred each year in China. In 2018, more than 3 million people suffered from a stroke, and more than 2 million people died from a stroke. Studies show that about 25% to 40% of transient ischemic attacks (TIA) or strokes occur in the posterior circulation. The subclavian and vertebral arteries are important blood vessels in the posterior circulation and are important original sites for ischemic strokes in the posterior circulation. About 20% of strokes in the posterior circulation are caused by extracranial vertebral artery stenosis (ECVAS). Endovascular intervention is the recommended treatment for ECVAS. It is effective in promoting the perfusion of brain tissue in the area of the responsible artery, thereby reducing the risk of stroke recurrence, improving neurological prognosis, and reducing symptoms. The drug-eluting stent is effective in reducing the incidence of postoperative restenosis (ISR), thus further reducing the long-term risk of stroke. Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials. The purpose of this study is to further investigate its long-term effectiveness in treating vertebral artery stenosis in the real world.
FIELD: medicine. SUBSTANCE: method involves applying biopolymer film to the gingival edge. Hydrophilic layer of the film contains Caviton and Voltaren. The film is applied with the hydrophilic layer contacting the gingiva, for 10-12 h. The procedure is repeated daily until microcirculation and hemodynamic properties of periodontium tissues come to norm. EFFECT: enhanced effectiveness of treatment. 6 dwg
A system and method for securely dispensing medication are described herein. The system includes a telemedicine center that communicates with medical assistant station and a medication distribution station located at a correctional facility and a physician center remote to the correctional facility. The medical assistant station transmits a request for medication to the telemedicine center. The telemedicine center verifies an identity of the medical assistant requesting the medication and transmits the request to the physician center. When the telemedicine center receives a confirmation to dispense medicine from the physician center, an identity of the physician transmitting the confirmation is verified. The telemedicine center then verifies an identity of an inmate to receive the medication, by way of the medication distribution station, and allows the medication distribution station to dispense the medication.
Phlebotomy was conducted at a frequency determined by the physician. Phlebotomy was interrupted when the study-defined target SF ≤ 100 μg/L was achieved. Phlebotomy was to be reinitiated when SF \> 100 μg/L, based on standard of care practice.
1,3,5(10)-8 alpha -oestratrienes of the following formula <IMAGE> in which R<1> is acyl and R<2> is lower alkyl are prepared. These compounds are obtained by oxidising a corresponding 3-hydroxy-13-R<2>-8 alpha -oestra-1,3,5(10)-trien-17-one with lead tetraacylate and rearranging the reaction product in the presence of a strong acid. The corresponding 1,3-hydroxy compounds are likewise prepared from the 1,3-diacyl compounds and can be converted into the corresponding diethers. The reduction of 17-keto compounds I into corresponding 17ss-hydroxy compounds is also described. The conversion of the said 17-keto compounds into 17ss-hydroxy-17 alpha R<4> compounds by reacting the 17-keto compounds with an organometallic compound which supplies the radical R<4>, which is a saturated or unsaturated, optionally substituted hydrocarbon group, is also described. The said compounds display favourable oestrogenic dissociation and can be used for the treatment of manifestations of oestrogen deficiency.
All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
Pharmaceutical prods. comprise salts of a polymer and a salt-forming pharmaceutically active cpd. The polymer contains acid gps. and is soluble or dispersible in H2O or conventional organic solvents. The polymer pref. contains 10-100% hydrophilic gps. derived from acrylic acid, vinylpyrrolidone, methacrylic acid or maleic anhydride, and 0-90% hydrophobic gps. derived from methyl, butyl or lauryl methacrylate, methyl or 2-ethylhexyl acrylate or styrene. It is pref. water-soluble or -swellable, and is not crosslinked. The prods. can be used as topical depot forms of alkaloids, local anaesthetics, analgesics and sulphonamides. In an example, a miotic ocular implant is produced by treating a soln. of acrylic acid/methyl acrylate copolymer in EtOH with pilocarpine, forming the soln. into a film, and cutting out lens-shaped pieces.
BACKGROUND: Immune thrombocytopenia (ITP) is an acquired immune-mediated bleeding disorder characterized by isolated thrombocytopenia. Its estimated yearly incidence in the pediatric population is 1.9-6.4/100,000. ITP in children is usually a self-limiting and benign disorder. The clinical management of children with ITP often remains controversial, as robust randomized trials on the management of this disorder are lacking. Treatments vary widely in clinical practice and existing guidelines from hematology societies on clinical management offer indications based largely on expert opinion rather than strong evidence.
MATERIALS AND METHODS: The Coagulative Disorder Working Group of the Italian Association of Pediatric Hematology and Oncology (AIEOP) developed this document to collect shared expert opinions on the management of newly diagnosed ITP, updating previous guidelines and providing recommendations to pediatricians. Each statement has been given a score expressing the strength of evidence, appropriateness and agreement among participants.
RESULTS: Clear-cut definitions of the clinical phases of the disease and clinical response are stated. Recommendations are given regarding the classification of bleeding symptoms, evaluation of bleeding risk, diagnosis, and prognostic factors. Specific recommendations for treatment include indications for first-line (intravenous immunoglobulins, steroids) and second-line (combined therapy, thrombopoietin receptor agonists, immunosuppressive drugs, rituximab) therapeutic agents, as well as hemorrhagic emergency and supportive treatment, including emergency splenectomy. The optimal follow-up schedule, the relation between ITP and vaccines and health-related quality-of-life issues are also discussed.
DISCUSSION: The panel achieved broad consensus on issues related to how to treat children with newly diagnosed ITP, providing a comprehensive review of all relevant clinical aspects.
The steroid enzyme 5 alpha -reductase is responsible for the conversion of testosterone to the more-potent androgen dihydrotestosterone (DHT). The catalytic cleavage of nucleic acid encoding 5 alpha -reductase by a ribozyme which selectively recognizes such nucleic acid reduces the level of expression of 5 alpha -reductase by mammalian cells including human cells treated with such ribozyme. The reduction of nucleic acid (e.g. mRNA) levels leads to a corresponding reduction of enzyme levels and dihydrotestosterone levels in surrounding tissues, thus providing a therapeutic effect. The transformation of 5 alpha -reductase producing cells with an expression vector containing a structural gene for a ribozyme is shown to decrease 5 alpha -reductase expression. Pharmaceutical compositions and methods useful for topically administering effective amounts of such a ribozyme to hair follicle cells also are exemplified.
Cardiovascular disease (CVD) afflicts nearly one-third of the adult population with all races and ethnicities represented in CVD prevalence. Unfortunately, a disparity exists such that the black population (BL) is disproportionately affected compared to other groups, including the white population (WH). While the underlying cause of this disparity is multifactorial, vascular dysfunction (i.e., impaired vasodilation and/or augmented vasoconstriction) is a key contributor. As has been previously observed, BL exhibit a heightened vasoconstrictor response to both pharmacological (e.g., alpha-adrenergic receptor agonists) and environmental (e.g., cold pressor test) stimuli compared to their WH counterparts. Additionally, reactive oxygen species (ROS) and the subsequent reduction in nitric oxide (NO) bioavailability may partially mediate this response.

Interestingly, the small blood vessels in the skin (cutaneous microvasculature) in BL, but otherwise healthy individuals, produce an impaired blood flow response to local heating when compared to age-, body mass index (BMI)-, and gender-matched WH. However, pre-treatment of the cutaneous microvasculature with either allopurinol or apocynin (xanthine oxidase inhibitor and NADPH oxidase inhibitor, respectively) abolishes this skin blood flow difference. These drugs inhibit possible sources of ROS, which, as mentioned, may be mediating the heightened vasoconstrictor response in BL. Accordingly, apocynin administration in previous research using an animal model ameliorates alpha-adrenergic receptor-mediated vasoconstriction, possibly due to a reduction in ROS. The role of xanthine/NADPH oxidase and the production of ROS on alpha-adrenergic receptor-mediated vasoconstriction in humans remains unknown.
This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor patient knows the treatment that the patient receives), multicenter, placebo-controlled (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), parallel-group (each group of patients will be treated at the same time), dose range finding study of JNJ-38518168 in patients with active RA despite concomitant MTX therapy. The study will consist a screening period, a 24-week placebo-controlled period and a 4-week follow-up period between the last dose and the last visit. The duration of participation in the study for an individual patient will be up to 34 weeks (including screening). The patients will be assigned to 1 of 4 treatment groups in a 1:1:1:1 ratio to placebo and JNJ-38518168 (3 mg or 10 mg or 30 mg). Safety assessments and evaluations to determine the efficacy of JNJ-38518168 to reduce the signs and symptoms of RA will be performed at study visits. Safety will be monitored throughout the study.
INTRODUCTION: Low back pain is common during pregnancy, affecting up to 76% of women. However, symptomatic lumbar disc herniation (LDH) is rare, occurring in about 1 in 10,000 pregnancies, with less than 2% progressing to cauda equina syndrome (CES). The overlap in symptoms between LDH and typical pregnancy-related conditions complicates both diagnosis and management. This review aims to enhance understanding of LDH and CES during pregnancy and provide a comprehensive overview of treatment options.
METHODOLOGY: A systematic review of the PubMed database was conducted following PRISMA guidelines, focusing on patient demographics, clinical presentation, diagnostics, treatment strategies, and outcomes.
RESULTS: Thirty-three case reports and series involving 51 pregnant women diagnosed with LDH and CES were analyzed. The average age was 33.2 years, with most symptoms occurring in the third trimester. Lower extremity pain (86.3%) and low back pain (78.4%) were the predominant symptoms, with 49.0% experiencing sphincter involvement. MRI was the primary diagnostic tool, identifying single-level disc herniation in 92.2% of cases. Antepartum spine surgery was performed on 74.5% of the women, predominantly through microdiscectomy, with 79.2% using general anesthesia. Post-surgery, 52.6% had cesarean sections, while 42.1% delivered vaginally. Adverse events were minimal (3.9%), and 62.7% of patients experienced favorable outcomes without neurological deterioration or maternal/fetal deaths.
CONCLUSION: Although rare, acute LDH and CES during pregnancy require prompt attention and intervention. MRI and emergent surgical treatment are generally safe and effective for both mother and fetus. Special surgical positioning and anesthesia management considerations are critical to minimizing risks and ensuring favorable outcomes.